Fig. 2From: Biokinetic and dosimetric aspects of 64CuCl2 in human prostate cancer: possible theranostic implicationsAn 85-year-old man affected by Gleason 4+3 PCa treated with EBRT, with rising PSA level (6.0Â ng/mL) and PSA doubling time of 15Â months. 64CuCl2-PET/CT images (axial and MIP) revealed focal and pathologic tracer uptake (arrows) in correspondence to the prostate apex close to the midline 1Â h after the injection (a). An important reduction of tracer uptake was observed 4 (b) and 24Â h (c) after the injection. Maximum intensity projection (d) visualized the differences in terms of uptake between the organsand prostate relapseBack to article page